Breathlessness in HIV positive and HIV negative participants Infections and Infestations Breathlessness in HIV positive and HIV negative participants
Conditions
Interventions
Part 1
There will be an initial visit specifically for the study, in addition to routine clinical care. At this visit informed consent will be taken by a qualified study team member. A
Sponsors
Royal Free London NHS Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: HIV positive participants: 1. HIV positive 2. Aged 18 years or older 3. Informed consent given 4. Chronic breathlessness (defined as MRC breathlessness score =2 persisting for at least 4 weeks and not due to an acute illness) 5. No definitive diagnosis to explain breathlessness (definitive diagnosis defined as patient or physician reported diagnosis substantiated by recent physiological investigations) 6. Able to participate for the duration of the study HIV negative participants: 1. Negative HIV test (performed as part of routine care) 2. Aged 18 years or older 3. Informed consent given 4. Chronic breathlessness (defined as MRC breathlessness score =2 persisting for at least 4 weeks and not due to an acute illness) 5. No definitive diagnosis to explain breathlessness (definitive diagnosis defined as patient or physician reported diagnosis substantiated by recent physiological investigations) 6. Able to participate for the duration of the study
Exclusion criteria
Exclusion criteria: All participants: 1. Unable to perform lung function tests. 2. Physical disability precluding the ability to complete a cardiopulmonary exercise test (for example wheelchair bound) 3. Pregnant 4. Unable to attend for investigations and review
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of participants with breathlessness in HIV positive and HIV negative groups due to: 1. Cardiac disease 2. Respiratory disease 3. Psychological causes 4. Deconditioning 5. Other For each participant group, the causes of breathlessness will be reported as a proportion due to each of the causes above at the end of the study. | — |
Secondary
| Measure | Time frame |
|---|---|
| The following are assessed at the baseline and at the end of the study? 1. Prevalence of depression in HIV positive and negative groups as defined by Patient Health Questionnaire (PHQ-9) score =5, assessed using the PHQ-9 2. Prevalence of severe depression in HIV positive and negative groups as defined by PHQ-9 score =20, assessed using the PHQ-9 3. Prevalence of anxiety in HIV positive and negative groups as defined by Generalised Anxiety Disorder assessment (GAD-7) score =5, assessed using the GAD-7 4. Prevalence of severe anxiety in HIV positive and negative groups as defined by GAD-7 score =15, assessed using the GAD-7 | — |
Countries
United Kingdom
Contacts
Public ContactAmina Jaffer
Outcome results
None listed